Tumour Registry Lung Cancer (TLK)
Completed
- Conditions
- Lung Cancer
- Registration Number
- NCT01192919
- Lead Sponsor
- iOMEDICO AG
- Brief Summary
Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.
- Detailed Description
The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
- histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy
- written informed consent
- start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent
Exclusion Criteria
- patients not receiving any systemic therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Documentation of actually used therapy forms in bronchial carcinoma requiring treatment 3 years per patient
- Secondary Outcome Measures
Name Time Method